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Novel, clinically relevant, approaches to shift energy
balance are urgently needed to combat metabolic dis-
orders such as obesity and diabetes. One promising
approach has been the expansion of brown adipose
tissues that express uncoupling protein (UCP) 1 and thus
can uncouple mitochondrial respiration from ATP
synthesis. While expansion of UCP1-expressing adipose
depots may be achieved in rodents via genetic and
pharmacological manipulations or the transplantation of
brown fat depots, these methods are difficult to use for
human clinical intervention. We present a novel cell
scaffold technology optimized to establish functional
brown fat–like depots in vivo. We adapted the biophys-
ical properties of hyaluronic acid–based hydrogels to sup-
port the differentiation of white adipose tissue–derived
multipotent stem cells (ADMSCs) into lipid-accumulating,
UCP1-expressing beige adipose tissue. Subcutaneous
implantation of ADMSCs within optimized hydrogels
resulted in the establishment of distinct UCP1-expressing
implants that successfully attracted host vasculature and
persisted for several weeks. Importantly, implant recipi-
ents demonstrated elevated core body temperature
during cold challenges, enhanced respiration rates,
improved glucose homeostasis, and reduced weight
gain, demonstrating the therapeutic merit of this highly
translatable approach. This novel approach is the first
truly clinically translatable system to unlock the ther-
apeutic potential of brown fat–like tissue expansion.
The unabated growth of the obesity epidemic and associated
diseases such as type 2 diabetes reflects the current lack of
effective strategies for intervention and treatment. Since
obesity results from an imbalance in the ratio of energy
intake to energy expenditure, it can be treated with reduced
caloric uptake and/or increasing energy expenditure. Brown
adipose tissue (BAT) and inducible brown-like cells in white
adipose tissue (WAT), currently referred to as beige or
brite adipocytes (1), possess the innate ability to dissipate
metabolic energy as heat through nonshivering thermogen-
esis. This is possible owing to the presence of the uncou-
pling protein (UCP) 1 (2), a long-chain fatty acid anion/
proton symporter (3), in the inner mitochondrial matrix,
which allows the return of protons after they have been
pumped across the mitochondrial inner membrane by the
electron transport chain, thereby bypassing ATP synthase.
While the importance of BAT for thermogenesis in smaller
mammals and human infants has been well documented
(4), only recent observations have demonstrated the pres-
ence of BAT in adult humans (5,6). These observations have
reversed the dogma that BAT is absent in adult humans and
have presented a new route for the treatment of obesity-
related disorders. Over 90% of the metabolic energy con-
sumed by activated BAT will be derived from the b-oxidation
of free fatty acids (FFAs) (7). Furthermore, many studies
have suggested that the amount of BAT correlates inversely
with BMI, raising the possibility that variations in the
amount of BAT may drive alterations in body weight (8).
Thus, increasing BAT mass may serve as a novel approach
to combat obesity and related disorders such as type 2 di-
abetes. This concept is supported by recent studies that
found evidence for metabolic enhancement, including the
reversal of type 1 diabetes (9) and resistance to diet-induced
obesity, in mouse models of BAT expansion (10) via trans-
plantation of existing BATs.
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Strategies for expanding BAT can be grouped into two
general categories: pharmaceutical/genetic intervention to
trigger endogenous BAT/beige differentiation pathways and
the ex vivo generation of BAT for implantation (11–15).
Gene therapy approaches, for example, the ectopic overex-
pression of the transcriptional regulator PRDM16 (14,16),
are powerful tools to investigate BAT biology but are diffi-
cult to apply clinically owing to the risks associated with
current gene therapy regiments (17). Pharmacological acti-
vation of differentiation pathways that drive a WAT-to-BAT
transition (“browning”) run the risk of affecting the func-
tion of other tissues and offer little control over the loca-
tion and temporal extent of BAT expansion. Similarly,
heterologous transplantation of existing BAT into immune-
compromised recipients has demonstrated the metabolic
impact of BAT expansion (10), but this approach has no
clinical translatability owing to a paucity of donor tissues
and the expected host-versus-graft rejection. Thus, we pro-
pose an alternative approach that takes advantage of current
progress in the field of bio-inspired hyaluronic acid (HyA)
hydrogels to engineer a matrix-assisted cell transplantation
(MACT) system for beige adipose tissue (BAT-MACT)
derived from the readily available, multipotent stem cell
(MSC)-containing, stromal vascular fraction of WAT (18).
RESEARCH DESIGN AND METHODS
Animals and Diets
Experiments were performed according to Association for
Assessment and Accreditation of Laboratory Animal Care
guidelines and approved by the University of California,
Berkeley, Animal Care and Use Committee. Eight-week-old
male C57BL/6J or FVB/NJ mice (The Jackson Laboratory)
were group housed for a 1-week acclimation period (tem-
perature 21 6 2°C, humidity 30–70%) in Tecniplast cages
filled with sani-chip bedding (Harlan) and then individ-
ually housed 1 week prior to implantation and adminis-
tration of high-fat (60%) diet (Teklad TD.06414).
Luciferase-expressing L2G85 (FVB/NJ) mice were used
as a cell source for experiments using bioluminescent
monitoring of implant viability and function.
Adipose-Derived MSC Isolation
Fat depots from L2G85 (FVB/NJ) or C57BL/6J mice,
perigonadal (visceral) or inguinal (subcutaneous), respec-
tively, were isolated from 3-month-old mice as previously
described (19).
In Vitro Differentiation of Adipose-Derived MSCs
Adipose-derived MSCs (ADMSCs) (initial density ;100
k cells/cm2) were cultured to postconfluence on tissue culture
polystyrene (TCPS) or adsorbed peptide surfaces. Differenti-
ation was induced for 3 days with 0.85 mmol/L insulin, 10
nmol/L triiodothyronine, 1 mmol/L dexamethasone, and 500
mmol/L isobutylmethylxanthine in high-glucose DMEM
(Invitrogen) with 10% FCS (Gibco) and penicillin/strepto-
mycin (P/S) (Gibco). The induced cells were then treated
with 0.85 mmol/L insulin and 100 nmol/L rosiglitizone in
high-glucose DMEM (Invitrogen) with 10% FCS and P/S
for 12 subsequent days. Before harvest with TRIzol, cul-
tures were treated with 5 mg/mL CL-316243 for 4 h. The
initial peptide screening differentiation experiments were
carried with the goal of determining the differentiation
outcome of an adhesion-selected cell fraction, a process re-
ferred to as “panning.” To this end, primary ADMSCs were
given 4 h to adhere onto the surface coating, cultures were
then PBS washed twice to remove less adherent cells within
the ADMSC population, and differentiation was induced as
described above (Fig. 1A–C). Experiments to determine op-
timal proportions of selected peptides were carried out with-
out washing off poorly adherent cells (Fig. 1D–F).
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed (20). Whole in vitro hydrogels were fixed with 4% para-
formaldehyde for 30 min at room temperature and imaged
within their MilliCell insert (Milipore) placed on coverslips.
mRNA
Tissue samples were suspended in RNAlater ICE (Ambion)
and stored at220°C. mRNA was isolated from RNAlater ICE
stabilized tissues or directly from in vitro cultures of mono-
layers or cell-laden hydrogels with TRIzol reagent (Ambion).
Tissue samples were homogenized with a Polytron PT 2100.
Assays were carried out on an ABI 7500 RT-PCR system with
TaqMan Universal Master Mix II and validated PrimeTime
primer probe sets (Integrated DNA Technologies). A first-
strand cDNA synthesis kit (Fisher) was used to transcribe
5 mg RNA/20 mL. cDNA (100 ng) was used per RT-PCR
reaction in triplicates. The D-D-CT method was used to com-
paratively assess mRNA quantity. All data are represented as
a sample’s value normalized to GAPDH relative to source
tissue–derived ADMSCs, source tissue, or endogenous BAT.
Protein Quantification and Western Blotting
A Pierce BCA kit was used to measure protein concen-
trations. Western blotting was accomplished with Novex
4–20% tris-glycine gels, iBlot Transfer Stacks (Invitrogen),
and a LI-COR Odyssey infrared imager with anti-UCP1
(Sigma-Aldrich) and anti–b-tubulin E7 clone (Developmen-
tal Studies Hybridoma Bank). Data are presented as UCP1
normalized to b-tubulin relative to endogenous BAT.
Synthesis of HyA Hydrogels
Modified HyA (500 kDa) was synthesized using previously
established methods (21). The acrylated HyA (AcHyA)-
C16 or AcHyA-Ag73 was synthesized by reacting peptides
(CGGKAFDITYVRLKF [10 mg] or CGGRKRLQVQLSIRT
[10 mg]) with AcHyA (25 mg, 10 mL deionized water)
at room temperature. To synthesize hydrogels, we dissolved
AcHyA (2 mg), AcHyA-C16 (6 mg), and AcHyA-Ag73 (2 mg)
in 0.3 mL triethanolamine buffer (0.3 mol/L, pH 8), incu-
bated for 30 min at 37°C, and subsequently matrix metal-
loprotease (MMP-13)–cleavable peptide (CQPQGLAKC) (3
mg in 50 mL triethanolamine buffer) was added to HyA
peptide solution. The crosslinker concentration was varied
to achieve complete crosslinking of available acrylate
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functionalities on the HyA macromers (;200 mmol/L).
The initial storage modulus of all hydrogels (in vitro and
in vivo) was measured consistently to be ;850 Pa.
BAT-MACT Generation
ADMSCs were cultured in vitro in DMEMwith 10% FBS and
1% P/S on TCPS. Two days postconfluency, differentiation
was induced with 0.85 mmol/L insulin, 10 nmol/L triio-
dothyronine, 1 mmol/L dexamethasone, and 500 mmol/L
isobutylmethylxanthine (for white adipocytes scaffolded
by unmodified AcHyA [WAT-MACT], triiodothyronine was
omitted from the cocktail). Three million cells per mL were
suspended in AcHyA-Ag73:C16 (1:3 molar ratio) just before
implantation (for WAT-MACT, cells were suspended in AcHyA).
Figure 1—Effects of adhesion ligands on ADMSC differentiation. A: Adhesion of ADMSCs to adsorbed peptides after 4 h incubation;
relative fluorescent units (RFUs) of adherent cells (n = 3). B: Neutral lipid staining of ADMSCs after differentiation on indicated adhesion
ligands (n = 3). C: UCP1 mRNA expression of WAT-derived murine ADMSCs that were differentiated on indicated adhesion substrate–
coated TCPS relative to undifferentiated ADMSCs (n = 3). D: UCP1 mRNA expression of WAT-derived ADMSCs differentiated on mixtures
of Ag73 and C16 relative to differentiated ADMSCs on TCPS (n = 6). E: Neutral lipid staining of WAT-derived ADMSCs on varied mixtures of
Ag73 and C16 relative to differentiated ADMSCs on TCPS (n = 6). F: UCP1 mRNA expression of WAT-derived ADMSCs differentiated on
mixtures of Ag73 and Ag32 relative to differentiated ADMSCs on TCPS (n = 6). Significance at *P < 0.05, **P < 0.01, and ***P < 0.001.
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The cell suspension was mixed with the MMP-13–cleavable
crosslinker at a final concentration of;200mmol/L (sufficient
to achieve a modulus of;850 Pa) and 100 mL of the forming
BAT-MACT was immediately injected to recipient mice.
Experiments where bioluminescent imaging (BLI) was
used to monitor the viability and function of the BAT-
MACTs, in conjunction with metabolic measures, were
performed in FVB/NJ mice with ADMSCs isolated from
perigonadal fat depots of syngenic L2G85 donor mice.
Experiments where metabolic parameters were assessed
without BLI monitoring were performed with C57BL/6J
mice implanted with BAT-MACTs generated with ADMSCs
isolated from the inguinal adipose depot.
In Vitro BAT-MACT
ADMSCs were cultured in vitro in DMEM with 10% FBS
and 1% P/S on TCPS. Three million subconfluent cells per
milliliter were suspended in the specific hydrogel and injected
into a Millicell transwell chamber (Millipore) in a 24-well
tissue culture plate (Falcon). After 2 days of culture in
DMEM with 10% FBS and 1% P/S, the differentiation
protocol described for the in vitro differentiation of ADMSCs
was implemented.
BLI
Imaging was accomplished with an IVIS Spectrum. Luciferin
(45 mL; 4 mg/mL i.p.) in PBS was injected into animals.
FFA-SS-Luc 100 mL of (1.4 mg/mL) intraperitoneal com-
pound was injected into mice. Once the BLI signal dropped
off (;40 min), the animals were removed to recover. Four
hours later, once all original BLI signal was extinguished,
1 mg CL-316243/g body wt i.p. was injected followed by
another dose of the FFA-SS-Luc.
Respirometry
Respirometry was performed with the Comprehensive Lab
Animal Monitoring System (CLAMS) (Columbus Instru-
ments). Measurements were taken over 24-h periods, and
average values were assessed (22). CL-316243 was admin-
istered to animals, and the 4-h preinjection was compared
with the 4-h postinjection time periods. Activity was mon-
itored in 1-min intervals of infrared beam breaks in x-, y-,
and z-axes and was found to be not significantly different
for any of the groups.
Serum Cytokine Measurements
A Bio-Rad Bio-Plex Pro Mouse Cytokine 23-Plex immu-
noassay kit was used per the manufacturer’s instructions
with a Bio-Rad MAGPIX system.
Rheology
Viscoelastic properties of the hydrogel were determined
using an oscillatory rheometer with parallel-plate geom-
etry (8 mm) and a gap height of 0.2 mm under 10%
constant strain and frequency ranging from 0.1 Hz to 10 Hz
at 37°C in a humidity-controlled chamber.
Cell Adhesion Assays
Purified peptides were suspended at 20 mmol/L in ultra-
pure water with 1% P/S. Peptide suspensions (20 mmol/L)
were allowed to adsorb to the 24-well TCPS plates (BD
Falcon) overnight at 4°C. Plates were then washed two
times with PBS. Twenty thousand primary ADMSCs sus-
pended in DMEM with 10% FBS and 1% P/S were added to
each well and incubated at 37°C for 4 h. Media and non-
adherent cells were removed and centrifuged to separate
the cells from media. The adherent and nonadherent cells
were then counted with the CyQUANT kit (Invitrogen).
Cold Challenge and Core Body Temperature
A Physitemp BAT-12 Microprobe thermometer was used
to measure core body temperature of mice rectally. Cold
challenges took place in a 4°C walk-in refrigerator ap-
proved for use in accordance with Association for Assess-
ment and Accreditation of Laboratory Animal Care
guidelines.
Serum Glucose and Glucose Tolerance Tests
Blood glucose was measured with a Nova Max blood
glucometer and Nova Max glucose test strips (Sanvita). Mice
were injected with an equivalent dose of glucose (167 mL of
300 g/L glucose). This dose was selected as a dose that the
median mouse weight would warrant to achieve the standard
glucose dose of 2 mg/g body wt generally used for a glucose
tolerance test.
Statistical Analysis
All data are presented as SEM analyzed using Prism
(GraphPad). Statistical significance was determined by
either one-way ANOVA followed by Tukey posttest or
unpaired two-tailed Student t test. Significance presented
at P , 0.05, P , 0.01, and P , 0.001.
RESULTS
Adhesion Ligands Enhance Beige Fat Differentiation
Cell adhesion and matrix interactions exert significant
control over MSC differentiation (23); however, no
screens have examined how these interactions affect the
browning of WAT-derived MSCs (ADMSCs). To this end,
ADMSCs were extracted from WAT (19) and cultured on
TCPS plates coated with specific peptides found to be
ligands for integrins and syndecans (Fig. 1A and Supple-
mentary Table 1). Differentiation was induced, and lipid
droplet accumulation (Fig. 1B) and UCP1 expression were
assessed (Fig. 1C). Our initial screens identified non-RGD
peptide sequences such as AG73 (CGGRKRLQVQLSIRT),
an adhesion ligand for a6 integrins and syndecan-1
(24,25), as particularly efficient in driving UCP1 expres-
sion of ADMSCs, while C16 (CGGKAFDITYVRLKF), an
a5/vb1/3 integrin–engaging ligand (26), induced lipid accu-
mulation. Interestingly, while all peptide-coated substrates
outperformed uncoated TCPS in UCP1 expression assays,
a combination of AG73 with C16 (1:3 molar ratio) had
significant effects on UCP1 expression (Fig. 1D and E).
Combining varied concentrations of AG73 with AG32
(CGGTWYKIAFQRNRK), another a6b1 integrin–engaging
ligand (25), we observed attenuated UCP1 expression (Fig.
1F). The impressive enhancement of UCP1 expression
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Figure 2—Bio-inspired HyA hydrogels. A: Schematic of the synthesis of AcHyA by sequential conjugation of adipic acid dihydrazide and
N-acryloxysuccinimide. B: Representation of the assembly of optimized hydrogel through crosslinking of C16-AcHyA to Ag73-AcHyA
macromers with an MMP-degradable crosslinker (not to scale). C: Time line of HyA hydrogel gelation. Gelation was considered complete
when the storage modulus (G9) exceeded the loss modulus (G99) (measured in Pascals). D: Photographs of AcHyA before (left) and 5 min
after (right) the addition of the crosslinker. E: Storage modulus of ADMSC suspended in uncrosslinked and crosslinked hydrogels cultured
in vitro after 72 h (n = 3). F: Three-dimensional reconstruction of in vitro ADMSCs in optimized hydrogel (red, UCP1; green, MitoTracker)
after completion of differentiation. G: UCP1 expression of differentiated ADMSCs with the optimized peptide mixture in monolayer and
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achieved by optimizing adhesion ligands is highlighted by
the fact that previous attempts to differentiate WAT-derived
MSCs into BAT yielded UCP1 levels significantly lower than
BAT-derived MSCs (11). In contrast, we find UCP1 expres-
sion in WAT-derived MSCs differentiated on optimized ad-
hesion ligands to be comparable with those of differentiated
BAT-derived MSCs in vitro (Supplementary Fig. 1).
Optimized Hydrogel Provides Instructive
Microenvironment for Beige Fat
Engagement with the extracellular matrix provides a crucial
factor in driving MSC differentiation through biophysical
properties and composition (27–29). Using our expertise in
biomaterials (20,30–32), we synthesized AcHyA macromers
(Fig. 2A) conjugated with the bioactive peptides. These func-
tionalized AcHyA macromers (AcHyA-Ag73 and AcHyA-
C16) were combined with specific MMP-sensitive peptide
crosslinkers at defined concentrations to form hydrogels
with precise physical characteristics and degradation kinet-
ics (Fig. 2B). The synthesis of hydrogel networks takes
advantage of the Michael-type addition reaction (i.e., attack
of the acrylate group by available cysteine thiols to form
a covalent bond) (33,34), which forms a defined hydrogel
scaffold within 5 min (Fig. 2C and D).
We verified that the ADMSCs embedded in the opti-
mized matrix were forming functional cell adhesions with
the hydrogel. By suspending ADMSCs in uncrosslinked
AcHyA-Ag73:C16 or unmodified AcHyA, we found that the
inclusion of adhesion peptides resulted in a significant
increase in the storage modulus of uncrosslinked hydrogels
seeded with ADMSCs, indicating that the adhesion pep-
tides enable cells to mechanically integrate the synthetic
extracellular matrix (Fig. 2E). The optimized hydrogel scaf-
fold allowed the ADMSCs to evenly distribute and differ-
entiate into UCP1-positive adipocytes in vitro without
direct cell-cell contact (Fig. 2F and Supplementary Fig. 2).
Importantly, culturing cells in AcHyA-Ag73:C16 hydrogels
significantly improved UCP1 expression of differentiated
ADMSCs in vitro compared with monolayers exposed to
adsorbed Ag73:C16 (Fig. 2G). Notably, unconjugated
hyaluronan- or RGD (CGGNGEPRGDTYRAY)-conjugated
hydrogels were not capable of inducing UCP1 expression
independent of Ag73 and C16 (Fig. 2H).
To produce a functional BAT-MACT, we isolated
ADMSCs from donor WAT, initiated differentiation in
vitro, and suspended the cells in Ag73 and C16 presenting
AcHyA macromers. BAT-MACTs were formed by mixing
cells (3*106/mL) with AcHyA macromers (3 wt%) and
a MMP-13–sensitive crosslinker. The cell suspension
was immediately injected with a 22.5-gauge needle into
the subcutaneous inguinal fat pad (or as noted) of recipient
animals. The viability of the implanted BAT-MACT was
monitored via bioluminescence using luciferase-expressing
donor cells delivered in a hydrogel or suspended in PBS.
Subcutaneous injections of luciferin adjacent to the implant
demonstrate luminescence for both conditions after im-
plantation. Importantly, the PBS-delivered ADMSCs pro-
duce little luminescence when the bioluminescent
substrate is introduced into general circulation. By deliv-
ering luciferin with intraperitoneal injections distant from
the BAT-MACT implant site, we observed massive signal
expansion during the first week, which declines to unde-
tectable levels 4 weeks postimplantation (Fig. 3A).
Owing to the rapid crosslinking kinetics, BAT-MACTs
form a distinct subcutaneous lobe upon injection that is
clearly brown/beige in appearance (Fig. 3B). BAT-MACTs
were highly vascularized on a macroscopic level, and thin
sections of implants demonstrated an extensive and consis-
tent vascular network throughout the implants (Fig. 3C).
Likewise, UCP1-positive and lipid droplet–accumulating
cells were evenly spread throughout the BAT-MACT (Fig.
3D). Interestingly, regions of the implant showed positive
staining for tyrosine hydroxylase, the rate-limiting enzyme
in the synthesis of catecholamines (Supplementary Fig. 3).
Tyrosine hydroxylase is essential for the production of nor-
epinephrine by sympathetic neurons and macrophages to
not only activate respiration but also maintain differentia-
tion status and function (35). UCP1 mRNA expression of
the implanted MACT was .10-fold higher than that of
comparable in vitro cultured MACTs (Fig. 3E) and reached
7–17% of the levels found in endogenous BAT (Supplemen-
tary Fig. 4). Importantly, PRDM16 and PPARg expression
in BAT-MACTs were comparable with those in endogenous
BAT (Fig. 3F), highlighting the potential of the MACT.
Immense differences of UCP1 induction within white
fat depots have been shown to be under genetic control
(36). We confirmed these differences by generating BAT-
MACTs from FVB/NJ and C57BL/6J mice. Similar to pre-
viously published findings, C57BL/6J visceral fat depots
produce significantly less UCP1 protein than FVB/NJ or
subcutaneously sourced C57BL/6J ADMSCs within our
BAT-MACT system (Fig. 3G). To assess the effect of im-
plant location, we analyzed two different implant sites in
the thoracic and inguinal regions for lipid droplets and
UCP1 expression. In BAT-MACTs from both implantation
sites, we observed multilocular lipid droplets, UCP1-
positive cells, and blood vessels with no apparent differ-
ence between the implantation sites. Impressively, UCP1
protein levels in both BAT-MACT sites reached ;30% of
BAT from the same animals (Fig. 3H). Importantly, inflam-
matory cytokines measured in serum were not upregulated
whatsoever by the BAT-MACT system; in fact, interleukin-2
comparable hydrogel (n = 4). H: ADMSCs differentiated in unconjugated HyA hydrogels, RGD-conjugated hydrogels, and Ag73:C16-
conjugated hydrogels. GAPDH normalized UCP1 mRNA expression relative to WAT (n = 5). Significance at *P < 0.05, **P < 0.01, and
***P < 0.001.
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Figure 3—BAT-MACT in vivo characteristics. A: Persistence of BAT-MACT over time monitored by luciferase activity in live animals (FVB/
NJ; n = 5); false color heat scale image indicating average (Avg) photon radiance. Max, maximum; Min, minimum; sr, steradian. B:
Macroscopic morphology of implants after 2 weeks. BAT-MACTs were removed after 14 days; fixed, cryosectioned, and stained with
DAPI; and stained for the vascularization marker endomucin (C ) or neutral lipids (green) and UCP1 (red) (D). E: mRNA expression of UCP1
relative to WAT using samples from differentiated ADMSCs plated on Ag73 and C16 peptide-coated TCPS or in Ag73- and C16-conjugated
AcHyA hydrogels cultured in vitro or implanted into recipient animals (FVB/NJ; n = 4, 3, or 6, respectively). F: PRDM16 and PPARg mRNA
expression normalized to GAPDH of BAT-MACTs after 2 weeks in vivo relative to endogenous BAT (FVB/NJ; n = 9). G: UCP1 protein
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was dissipated (Fig. 3I). Therefore, the BAT-MACT sys-
tem allows for the measurement of metabolic effects in-
dependent of inflammatory artifacts.
Beige Fat Implantation Enhances Metabolic Profiles of
Recipients
To determine the metabolic impact of BAT-MACTs, we
examined the respiratory capacity of animals augmented
with a BAT-MACT or WAT-MACT. HyA matrixes have
been shown to aid in the development and persistence
of WAT (37,38), and WAT-MACTs formed fatty implants
that were well vascularized, contained extensive lipid
stores, and had undetectable UCP1 expression (Supple-
mentary Fig. 5). The BAT-MACT implanted animals
displayed significantly enhanced VO2 and reduced re-
spiratory exchange ratio, recapitulating the elevated
fatty acid utilization and respiration after classical BAT
activation (Fig. 4A and B). Furthermore, BAT-MACT aug-
mented animals were significantly more responsive to
CL-316243, a b3-specific adrenergic agonist (Fig. 4C). To
verify that FFAs would be taken up by BAT-MACTs, we
used a recently developed optical probe for fatty acid
uptake (39) and observed that an intraperitoneal injection
of the probe was robustly taken up by BAT-MACTs. Impor-
tantly, as previously shown for endogenous BAT (40), in-
jection of a b3-adrenergic agonist significantly enhanced
fatty acid uptake rates by the BAT-MACTs (Fig. 4D).
To test the impact of BAT-MACTs on thermogenesis,
we examined core body temperature at room temperature
(21°C) and over 24 h of 4°C. Body temperatures of BAT-
MACT recipients were higher throughout the cold challenge
as well as at room temperature (Fig. 4E). Thermography
revealed that the implant is distinctly thermogenic (Sup-
plementary Fig. 6). Importantly, this thermogenic effect
was dependent on the amount of cells implanted (Fig.
4F) and the environmental temperature (Fig. 4G). Using
C57BL/6J mice as a model for diet-induced obesity, we
measured the impact of BAT-MACT impact on weight
gain and glucose homeostasis. Animals implanted with
BAT-MACTs and housed at 21°C for 2 weeks gain signifi-
cantly less weight when fed a 60% fat diet compared with
PBS-delivered ADMSCs, cell-free matrix, or WAT-MACTs
(Fig. 5A) in spite of slightly higher food consumption
(Fig. 5B). Extended monitoring of weight gain identified
that the reduction of weight gain was significant within
2 weeks post–BAT-MACT implantation and concomitant
high-fat feeding. The difference in weight gain was sus-
tained over a time period coinciding with the lifetime
of the BAT-MACT cells as measured by bioluminescence
(Fig. 5C).
After 2 weeks, serum triglyceride levels were found to
trend lower and serum free fatty acids were reduced in
animals augmented with BAT-MACTs (Fig. 5D and Sup-
plementary Fig. 7). Accompanying the reduced weight
gain and serum FFAs, resting blood glucose levels (Fig.
5E) and glucose tolerance (Fig. 5F) were improved in
BAT-MACTs but not WAT-MACTs, cell-free implants, or
matrix-free implants of BAT-like cells.
DISCUSSION
Expansion of UCP1-positive tissue holds exciting poten-
tial to combat obesity and related disorders (41). How-
ever, few practicable approaches for clinical deployment
have been presented thus far. This novel strategy to in-
tegrate WAT-derived MSCs with bioactive hydrogels
bespoke to enhance differentiation, support tissue forma-
tion, and survival upon implantation provides the re-
quired core technology for autologous expansion of BAT
mass in patients. ADMSCs are easily extractable and
abundant and are already used in regenerative medicine
(18). ADMSCs used in this study were only partially pu-
rified; further gains in differentiation effectiveness could
be anticipated by sorting for UCP1-enriching markers
such as Sca-1 (13), CD24, CD29 (15,42), and CD137 (43).
Hydrogel-based therapies are minimally invasive ther-
apeutic options that will complement pharmacological
and cell-based approaches (44). We selected HyA as the
core scaffold of our matrix for its biocompatibility, bio-
degradability, and nonimmunogenic properties and its
role in tissue development and repair (30). Recently,
HyA has been shown to augment integrin-mediated
mechanotransductive signaling (45) and likely plays an
essential role in the overall effect that our matrix has
on the differentiation of ADMSCs. Similar hydrogel sys-
tems have been proposed for clinical use that used cross-
linkers and adhesion ligands that directly compete for
attachment to the available functional groups on core
polymeric chains within the hydrogel. These systems
have struggled with compromised crosslinking efficien-
cies, unbound adhesion ligands preventing cell association
with the matrix, and low–molecular weight core struc-
tures that degrade too rapidly to be useful (46).
Matrix stiffness plays an important role in cell fate
determination and should be a critical design feature of cell
transplantation systems (27). We have developed a modular
hydrogel system that allows for modulus and biological prop-
erties of the hydrogel to be tuned independently. This modular
approach to tissue engineering may be essential to target an
optimal net modulus for the development and maintenance
expression of BAT-MACTs generated with ADMSCs from visceral or subcutaneous FVB/NJ or C57BL/6J mice 2 weeks postimplantation
into a syngenic recipient relative to endogenous BAT (n = 3). NS, not significant. H: UCP1 protein expressed in BAT-MACTs of different
implant sites after 2 weeks in vivo relative to endogenous BAT (FVB/NJ; n = 5). I: Serum cytokine levels measured 2 weeks postimplantation
of BAT-MACT or the same ADMSCs delivered via PBS. Animals were administered the 60% fat diet for the duration of this study
(C57BL/6J; n = 6). IL, interleukin. Significance at **P < 0.01 and ***P < 0.001.
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of our BAT-MACT by allowing us to integrate and indepen-
dently tune the crosslinking modulus and modulus that
cells produce through ligand-specific mechanotransduction
observed in Fig. 2E.
We have already shown that some ADMSCs spontane-
ously differentiate into UCP1-expressing cells in vitro
using our bio-inspired hydrogel (Fig. 2F). In our future
studies, generation of UCP1-positive adipocytes could be
Figure 4—Metabolic effects of BAT-MACTs 2 weeks postimplantation. A: Average VO2 rate over 24 h (FVB/NJ; n = 4). B: Average
respiratory exchange ratio (RER) over 24 h (FVB/NJ; n = 4). C: Average VO2 rate 4 h before and after b-adrenergic agonist CL-316243
(CL) was administered (FVB/NJ; n = 4). D: Fatty acid uptake of BAT-MACTs under basal and CL-316243–stimulated conditions (FFA-SS-
Luc) (FVB/NJ; n = 3). SR, steradian. E: Core body temperature during a 24-h cold challenge (4°C) (FVB/NJ; n = 6). F: Core body temperature
after a 6-h cold challenge (4°C) of animals implanted with the indicated number of ADMSCs in 100 mL optimized hydrogels on a normal
chow diet (FVB/NJ; n = 6). G: Average VO2 rate of mice implanted with BAT-MACT or comparable cells delivered in PBS during the 10–14
days postimplantation in a temperature-controlled CLAMS unit (C57BL/6J; n = 4). Explanation of controls: WAT-MACT, ADMSCs differ-
entiated without triiodothyronine embedded in a peptideless HyA hydrogel; cells-PBS, equivalent number of differentiated ADMSCs de-
livered in 100 mL PBS. Significance at *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figure 5—Beige fat expansion promotes improved metabolic profiles in C57BL/6J mice. A: Weight gain of mice after 2 weeks of
consuming 60% fat diet and being implanted with BAT-MACT or controls receiving cells with no matrix, cell-free matrix, or WAT-MACTs
(n = 6). B: Cumulative kilocalories consumed by the animals over 2 weeks. NS, not significant. C: Body weight of animals injected with
matrix-free cells or BAT-MACTs consuming a 60% fat diet over the course of 6 weeks (n = 4). D: Serum nonesterified fatty acid (NEFA)
concentration. E: Resting blood glucose concentrations. F: Glucose tolerance test area under curve (AUC) (time points: 0, 20, 30, 60, and
120 min) with an identical dose of glucose given to animals after 2 weeks of consuming 60% fat diet and being implanted with either BAT-
MACT or matrix-free control (n = 6). Significance at *P < 0.05, **P < 0.01, and ***P < 0.001.
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enhanced with matrices presenting heparin-binding
growth factors, specifically, BMP7 and FGF21, which
have been implicated in BAT differentiation (47). This
objective is feasible, as heparin-binding growth factors
can be associated with the matrix through the addition
of thiolated heparin to the AcHyA (20). Ultimately, there
is potential to generate a cell-free matrix that would
orchestrate WAT transdifferentiation.
Our current generation of BAT-MACTs was viable for
;30 days in vivo after ;10 days in vitro culture. Duration
of the implants is likely determined by a combination of
the matrix susceptibility to biodegradation, through the
MMP-sensitive crosslinker and HyA backbone, and the
life span of brite/beige cells (;50 days) (48). Importantly,
we developed MMP-sensitive crosslinkers (30) to enable
tissue remodeling and recruitment of host vasculature
(Fig. 3C). MMP-13 has been shown to be essential for vas-
cularization processes (49), and its expression is one of the
most significantly upregulated MMPs during the differenti-
ation of adipocytes (50). Additionally, crosslinkers designed
to be sensitive to other MMPs appear to degrade too rapidly
in vivo to be used for these applications.
In vivo experiments with BAT-MACTs validated prior
notions about the metabolic impact of BAT expansion.
Recipients exposed to cold demonstrated that a 100-mL
BAT-MACT implant had a significant effect on thermogen-
esis in a cell-number–dependent manner. BAT-MACTs in-
creased respiration rates and fatty acid utilization, reduced
weight gain, and improved glucose homeostasis. These
results are in line with recent reports demonstrating that
transplantation of primary BAT fragments into mice can pre-
vent diet-induced obesity (10). It remains to be determined
whether these beneficial effects are solely due to the increased
caloric expenditure afforded by the implant or if they also rely
on an endocrine component such as interleukin-6 (10) or
other factors secreted by UCP1-positive adipose.
In summary, beige adipose tissue can be engineered
using an optimized bio-inspired HyA hydrogel system in
conjunction with WAT-derived stem cells and can persist
under defined spatio-temporal conditions to affect body
temperature, energy homeostasis, weight gain, and in-
sulin sensitivity. These data from our preclinical model
demonstrate the feasibility of a novel autologous trans-
plantation-based antiobesity approach with a clear path
for ultimate translation into clinical practice. Importantly,
the BAT-MACT approach will facilitate systematic evalu-
ation of the metabolic effects of BAT expansion and the
underlying biological mechanisms.
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